1. Home
  2. IFRX vs AREC Comparison

IFRX vs AREC Comparison

Compare IFRX & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.16

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Logo American Resources Corporation

AREC

American Resources Corporation

SELL

Current Price

$0.93

Market Cap

220.4M

Sector

Energy

ML Signal

SELL

Company Overview

Basic Information
Metric
IFRX
AREC
Founded
2007
2013
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Coal Mining
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
225.5M
220.4M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
IFRX
AREC
Price
$1.16
$0.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
★ $8.41
$6.00
AVG Volume (30 Days)
1.0M
★ 2.1M
Earning Date
11-03-2026
11-27-2026
Dividend Yield
N/A
★ 4.18%
EPS Growth
N/A
★ 223.53
EPS
N/A
★ 0.63
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3,533.33
P/E Ratio
★ N/A
$1.61
Revenue Growth
★ N/A
N/A
52 Week Low
$0.80
$0.91
52 Week High
$2.95
$4.80

Technical Indicators

Market Signals
Indicator
IFRX
AREC
Relative Strength Index (RSI) 30.72 31.01
Support Level $0.81 $0.91
Resistance Level $2.44 $1.37
Average True Range (ATR) 0.15 0.11
MACD -0.03 0.02
Stochastic Oscillator 1.56 4.26

Price Performance

Historical Comparison
IFRX
AREC

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About AREC American Resources Corporation

American Resources Corp is engaged in the aggregation, recovery, recycling, and sale of recovered metal and steel materials. The company operates through two segments: Corporate and Electrified Materials. The Electrified Materials segment focuses on processing and recycling recovered metal and steel products.

Share on Social Networks: